1-3 of 3
Malgorzata Kopera, MD
Close
Sort by
Journal Articles

Treosulfan + Fludarabine +/− Thymoglobulin - An Effective Low Toxicity Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia.

Jerzy Holowiecki, Sebastian Giebel, MD, Jerzy Wojnar, MD, Malgorzata Krawczyk-Kulis, MD, Iwona Wylezol, MD, Miroslaw Markiewicz, MD, Tomasz Kruzel, MD, Aleksandra Holowiecka-Goral, MD, Malgorzata Kopera, MD
Journal: Blood
Blood (2005) 106 (11): 5309.
https://doi.org/10.1182/blood.V106.11.5309.5309
Published: 2005
Journal Articles

Daunorubicin, Cytarabine and Fludarabine (DAF) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Phase II Study by the Polish Adult Leukemia Group (PALG).

Jerzy Holowiecki, Sebastian Grosicki, MD, Slawomira Krzemien, MD, Aleksander Skotnicki, Krzysztof Warzecha, Barbara Zdziarska, MD, Beata Stella-Holowiecka, MD, Malgorzata Krawczyk-Kulis, MD, Malgorzata Kopera, MD, Maria Wojciechowska, MD
Journal: Blood
Blood (2004) 104 (11): 4507.
https://doi.org/10.1182/blood.V104.11.4507.4507
Published: 2004
Journal Articles

Immunophenotyping to Detect Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia - Feasibility and Prognostic Significance.

Jerzy Holowiecki, Sebastian Giebel, MD, Krystyna Jagoda, PhD, Malgorzata Krawczyk-Kulis, MD, Beata Stella-Holowiecka, MD, Slawomira Kyrcz-Krzemien, MD, Monika Paluszewska, MD, Malgorzata Kopera, MD, Wlodzimierz Medrek, MD, Grazyna Bober, MD, Jacek Najda, MD
Journal: Blood
Blood (2004) 104 (11): 4489.
https://doi.org/10.1182/blood.V104.11.4489.4489
Published: 2004